Mr Michael L Kichline > Dechert LLP > Philadelphia, United States > Lawyer Profile

Dechert LLP
CIRCA CENTRE, 2929 ARCH STREET
PHILADELPHIA, PA 19104-2808
United States

Work Department

Litigation

Career

Michael L. Kichline is a co-leader of the firm’s global securities and corporate governance litigation practice. His more than two decades of experience span a diverse range of complex, high-stakes matters, including securities class actions, derivative suits, M&A disputes, ERISA, consumer class actions, business torts, contract disputes, legal malpractice defense and appellate matters.

 

 

Memberships

Trustee, Philadelphia Bar Foundation; Litigation Section, American Bar Association; Member, National Association of Corporate Directors; Member, Temple American Inn of Court; Member, Supreme Court Historical Society; Member, Eastern District of Pennsylvania Historical Society; Member, Pennsylvanians for Modern Courts, Member, Pennsylvania Business Council

Education

Temple University, B.A., 1988, magna cum laude; Temple University Beasley School of Law, J.D., 1991, magna cum laude, member of the Moot Court Honor Society

Lawyer Rankings

United States > Dispute resolution > Securities litigation: defense

Dechert LLP has securities litigators in offices across the US and frequently handles class actions, shareholder derivative suits, mutual fund litigation, broker-dealer disputes and regulatory enforcement proceedings. The ‘very likableDavid Kistenbroker, who practices in both New York and Chicago, is global co-chair of the trial, investigations and securities group. He acted for Anavex Life Sciences Corporation and its officers in a 10b5 case that alleged false and misleading statements were made about the efficacy of the company’s experimental Alzheimer’s drug; Joni Jacobsen in Chicago also played a key role in that case. The same team also acted for Antares Pharma Inc in several cases, including a suit alleging that the company provided insufficient information to the FDA in support of Xyosted and overstated its approval prospects. In New York, firm chairman Andrew Levander, who handled a 33 Act claim for CHC Group, and global litigation head Matthew Larrabee are recommended, as is Michael Kichline in Philadelphia.